Evonetix announces agreement for revolutionary Gene Synthesis Platform with Analog Devices
Cambridge, UK, 06 December 2023 – EVONETIX LTD (‘Evonetix’), the company developing semiconductor scale technology to improve access to gene synthesis, announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc. (ADI), a global semiconductor leader. This agreement signals the continuation of the long-standing combined work of both companies,…
Evonetix places first DNA synthesis development platform at Imperial College London
External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology, in preparation for customer use and commercialization
Evonetix unveils new branding to align with its vision for gene-length DNA synthesis
Reflects evolution of the Company from research and development towards scale-up and commercialization
Evonetix delivers first chip-synthesized DNA to the University of Cambridge
First delivery and use of DNA manufactured using Evonetix’s unique thermally controlled synthesis technology. Key milestone in the development of Evonetix’s desktop DNA synthesis platform
Evonetix closes $24 million USD (£20 million) financing
Oversubscribed round led by Foresite Capital Funding will enable development of DNA synthesis chip technology to commercial scale
Evonetix commences early access program for DNA synthesised by thermal control on its semiconductor chip
Cambridge, UK - Evonetix, the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene…
Evonetix appoints Colin McCracken as Chief Executive Officer
Cambridge, UK - EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, announces the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Evonetix granted patent for DNA data storage and retrieval method
Evonetix Ltd, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, announced it has been granted patent GB 2576304 for its novel method for DNA data storage and retrieval.
Evonetix appoints Dr Michael Daniels as Head of Product Management
Evonetix Ltd, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the appointment of Michael Daniels, PhD, as Head of Product Management.
Evonetix and Analog Devices collaborate on third-generation DNA synthesis platform
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced a collaboration with leading, global high-performance analog technology company, Analog Devices, Inc. The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon…
Evonetix raises $30 million USD (£23 million GBP)
Evonetix Ltd, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital.
Evonetix expands facilities and relocates to central Cambridge
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Evonetix appoints Stephanie Brooking as Head of Product Management
Evonetix Ltd, the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announced it has appointed Stephanie Brooking as Head of Product Management.
Evonetix establishes scientific advisory board
Evonetix Ltd, the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announces the formation of its scientific advisory board (SAB).
Evonetix named Best Synthetic Biology Company at OBN Awards
Evonetix, the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, has received the award for “Best Emerging Synthetic Biology Company” at the 10th Anniversary of the Oxford Bioscience Network (OBN) Awards.
Evonetix partners with LioniX International to enable DNA synthesis at scale
Evonetix, the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, will collaborate to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis.
Evonetix makes key appointments to support development of novel gene synthesis technology
Evonetix Ltd, the company pioneering an innovative approach to scalable and high-fidelity gene synthesis, announced today that it has expanded its team three-fold, following a successful series A round of £9 million ($12.3M) to support the development of the company’s technology.
Evonetix awarded Innovate UK funding for £1.3 million gene synthesis project
Evonetix Ltd, the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it had been awarded substantial funding to support the development of a novel enzymatic approach to DNA synthesis. Innovate UK, the UK’s innovation agency, will co-fund the £1.3 million project, which will be undertaken in collaboration with Durham…
Evonetix raises £9 million to develop its highly novel gene synthesis platform
Evonetix Ltd, the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, has completed a £9 million ($12.3 million) financing to advance the development of its technology.